European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Luxembourg/Heidelberg, July 1, 2025 - Precisis, a Heidelberg-based MedTech innovator developing personalized neurostimulation technology for neurological disorders, announced today the closing of a €20 million venture loan from the European Investment Bank (EIB). This funding complements the company’s recently started efforts to raise an additional €37 million in equity financing as part of its Series B round. Only a few European MedTech Companies have received this level of EIB support to date.
The EIB’s investment underscores the transformative potential of EASEE®, Precisis’ lead product. This is a CE-certified, minimally invasive neurostimulator for focal epilepsy already approved and reimbursed in Europe and the UK. By providing targeted therapy through a patient-friendly implant with proven clinical efficacy and comfort, Precisis is well-positioned for rapid commercial expansion across the UK and Europe, alongside preparations to enter the U.S. market. Building on this foundation, Precisis is also already developing a next-generation system that will utilise advanced artificial intelligence to enable a closed-loop neurostimulation approach, capable of real-time monitoring and adaptive therapy tailored to each patient’s unique needs. The EIB’s support validates Precisis’ clinical and commercial progress, bolstering confidence in its ability to advance neurological care.
International approval strengthens German MedTech vision
“This funding by the European Investment Bank is a strong endorsement of our platform and vision,” said Karl Stoklosa, CEO of Precisis. “It also marks a pivotal point in our growth. With the first wave of capital secured, we’re now actively engaging with investors to complete the round and accelerate our entry into the U.S. market. The opportunity for co-investors to join at this stage—before major global expansion—is significant.”
About Precisis GmbH
Based in Heidelberg, Precisis is developing novel neurostimulation systems to treat functional brain disorders. Its flagship product, EASEE®, delivers targeted electrical stimulation to the brain via a minimally invasive, patient-friendly implant. With European approval and reimbursement secured, Precisis is now focused on expanding treatment access and entering the U.S. market.
About the European Investment Bank (Precisis RDI)
The EIB is the EU’s long-term lending institution, supporting innovation, infrastructure, and strategic sectors across Europe. Its venture debt program provides growth financing for high-impact companies advancing healthcare, sustainability, and technological leadership.